tbuckley/cabot-search huggingface dataset:
Diagnostic Value of Tc-99m HIG Scintigraphy in the Detection of Acute Appendicitis
Authors: ERHAN VAROĞLU, K. YALÇIN POLAT, GÜNGÖR TAŞTEKIN, FATIH AKÇAY, CAFER POLAT
Journal: Clinical Nuclear Medicine (1996)

The diagnosis of acute appendicitis, which is the most important cause of abdominal infections, may be done with a scoring system based on patient history, and physical and laboratory examinations. Recently, various scintigraphic techniques have also been used for the detection of acute appendicitis. Two patients with suspected acute appendicitis were investigated scintigraphically to assess the value of Tc-99m labeled HIG in the diagnosis of clinically suspected acute appendicitis. Scintigraphic results suggested that HIG scintigraphy is a rapid, important, accurate, and safe method in the detection of acute appendicitis.
<i>Notes from the Field</i>: Baseline Assessment of the Use of Ebola Rapid Diagnostic Tests — Forécariah, Guinea, October–November 2015
Authors: Jennifer Y. Huang, Frantz Jean Louis, Meredith G. Dixon, Marcel Sefu, Lon Kightlinger, Lise D. Martel, Gayatri C. Jayaraman, Abdou Salam Gueye
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The Ebola virus disease (Ebola) epidemic in West Africa began in Guinea in early 2014. The reemergence of Ebola and risk of ongoing, undetected transmission continues because of the potential for sexual transmission and other as yet unknown transmission pathways. On March 17, 2016, two new cases of Ebola in Guinea were confirmed by the World Health Organization. This reemergence of Ebola in Guinea is the first since the original outbreak in the country was declared over on December 29, 2015. The prefecture of Forécariah, in western Guinea, was considerably affected by Ebola in 2015, with an incidence rate of 159 cases per 100,000 persons. Guinea also has a high prevalence of malaria; in a nationwide 2012 survey, malaria prevalence was reported to be 44% among healthy children aged ≤5 years. Malaria is an important reason for seeking health care; during 2014, 34% of outpatient consultations were related to malaria.
The Future of Obamacare
Authors: Jonathan Oberlander
Journal: New England Journal of Medicine (2012)

Interview with Dr. Jonathan Oberlander on the political future of health care in the United States. (20:11)Download Given the results of the 2012 elections, the threat of repeal that has hung over the Affordable Care Act has faded. So what is the future of Obamacare? What challenges and conflicts lie ahead on the long road of implementation for health care reform?
Abstract 1872: A prospective cohort study of shift work and pancreatic cancer risk in Japanese men
Authors: Yingsong Lin, Shogo Kikuchi, Kiyoko Yagyu, Michiko Kurosawa, Akiko Tamakoshi
Journal: Cancer Research (2011)

Abstract The etiology of pancreatic cancer remains largely unknown. The lack of effective screening tools coupled with the dismal prognosis make it crucial to identify modifiable risk factors that can be incorporated into a prevention strategy for pancreatic cancer. Approximately 15-20% of the working population in industrialized countries engages in night-shift work, drawing considerable interest in the effect of such work patterns on health, including on the formation of cancers. We analyzed data from a large-scale, prospective cohort study of middle-aged and elderly Japanese individuals (the JACC Study) to test the hypothesis that rotating shift work might be associated with an increased risk of pancreatic cancer. Our analysis was restricted to 18,745 men who were 40-60 years of age at baseline (1988-1990) and who reported working full-time or were self-employed. Information on occupation and lifestyle factors was collected using a self-administered questionnaire. Mortality from pancreatic cancer was ascertained from the causes of death recorded on death certificates. The Cox proportional hazards model was used to estimate relative risk (RR) and confidence interval (CI) for the association between shift work and pancreatic cancer risk. A total of 70 pancreatic cancer deaths were observed until Dec 31, 2008. Overall, we found no statistically significant increase in the risk of death from pancreatic cancer associated with rotating shift work. As compared to day-shift workers, the RRs were 0.89 (95%CI: 0.40-1.96) for rotating shift workers and 0.27 (0.04-1.93) for fixed night-shift workers, after adjustment for potential confounding factors. In conclusion, shift work is not associated with the risk of death from pancreatic cancer in this cohort of Japanese men. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1872. doi:10.1158/1538-7445.AM2011-1872
Effects of Early and Vigorous Exercise on Recovery from Infectious Hepatitis
Authors: Lawrence H. Repsher, Robert K. Freebern
Journal: New England Journal of Medicine (1969)

To compare the effect of strenuous exercise on recovery time in 199 American servicemen in Vietnam with infectious hepatitis to that in 199 patients with infectious hepatitis treated in the customary fashion, the exercise group was started on the program of strenuous exercise for approximately three hours daily at the time their symptoms were considered to be slight, irrespective of the degree of liver-function abnormality. No statistical difference was found between the two groups in the duration of elevation of serum bilirubin or in relapse rate. Exercise did not adversely affect those whose maximum serum bilirubin was greater than 3.0 mg per 100 ml or those over 30 years old. No difference in duration of disease was found in those who were involved in strenuous activity at the time of onset of illness as compared to those involved in light activity. Strenuous activity does not appear to have any adverse effect on the acute course of infectious hepatitis in previously healthy young men.
CN-15 * ADVERSE EFFECTS OF BEVACIZUMAB IN BRAIN TUMOR PATIENTS
Authors: T. Pawar, H. Ladha, J. Mandel, M. Gilbert, B. O'Brien, M. Hamza, T. Armstrong
Journal: Neuro-Oncology (2014)

BACKGROUND: Bevacizumab is humanized monoclonal antibody inhibiting angiogenesis and the only FDA approved treatment for recurrent glioblastoma. The aim of this study was to look at the occurrence of various adverse effects associated with use of bevacizumab in recurrent glioblastoma. METHODS: In this retrospective chart review, we studied 280 patients with recurrent glioblastoma treated with Bevacizumab between 2005-2011 to characterize the known adverse effects of bevacizumab including hypertension, grade 3-4 myelosuppression, wound healing complications, thrombo-embolic events, stroke, hemorrhage and gastrointestinal complications. RESULTS: The study population included 168 males and 112 females. The median age was 53.5 years(range 8.1-81.3). TREATMENT: Bevacizumab only(58), Bevacizumab + CPT(11), Bevacizumab + TMZ(32) or Bevacizumab + Other(34). Patients were treated at recurrence(1st = 96; 2nd = 126, 3rd = 58). Hypertension was the most common adverse effect occurring in 131(49%). The median duration from treatment start to development was 82 days (Range 7-1143). However, only 33(25%) were started on antihypertensive medication. Grade 3-4 Myelosuppression occurred in 52(19%)causing treatment discontinuation in 8. Thrombo-embolic events were reported in 5%(15) patients including DVT(9), PE(2), Central venous thrombosis(1) and Stroke(3). Thirty-six patients (13%) were on anti-coagulant medication at bevacizumab initiation. Median time to a thromboembolic complication was 113 days (Range 8-1145). Wound healing complications were noted in 7(3%) patients, 3 craniotomy dehiscence and 4 at soft tissue sites. Five patients (2%) developed GI complications, including perforations(3), pancreatitis(1), and diverticulitis(1). Median time to development was 92 days(Range 10-651). There was a high rate 46%(129) of grade 3-4 lymphocytopenia; median time to develop lymphocytopenia was 50 days(Range = 3-564). CONCLUSION: The range of toxicities was similar to other reports. Interestingly, hypertension was the most common adverse effect and was often not treated. The high incidence of lymphocytopenia may have implications for combination with immunotherapies. These findings underscore the need to develop predictive models to identify patients at high risk for serious treatment-related toxicities.
498 INTRAHEPATIC HBSAG REDUCTION AFTER PEGINTERFERON TREATMENT IN HBEAG NEGATIVE AND HBEAG POSITIVE CHRONIC HEPATITIS B IS ASSOCIATED WITH SERUM HBSAG DECLINE
Authors: P. Arends, V. Rijckborst, M. Sonneveld, B. Hansen, H. Janssen
Journal: Journal of Hepatology (2012)
Abstract 2617: MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changes <i>in vitro</i> and i<i>n vivo</i>
Authors: Vijay R. Baichwal, Brita Brown, Rosann Robinson, Daniel Cimbora, Daniel Wettstein, Andrew P. Beelen, Gary G. Mather, Robert O. Carlson
Journal: Cancer Research (2011)

Abstract Introduction: MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor in clinical development. It is broadly active in xenograft models with anti-tumor activity ranging from tumor regression to tumor growth inhibition in many cancer types including colon, gastric, ovarian, prostate, breast, lung and myeloid leukemia. Here we evaluate the effect of MPC-3100 on stability of client proteins in cells and xenograft tumors. We also determine the effect on Hsp70 protein levels, a biomarker of Hsp90 inhibition, in peripheral blood mononuclear cells (PBMCs) from cancer patients receiving MPC-3100. Methods: Her2, Akt, Cdk4, c-Raf and Hsp70 client protein levels were monitored in cell culture with protein immunoblots. Formalin-fixed, paraffin-embedded sections of xenograft tumors from mice dosed orally with MPC-3100 were analyzed by immunohistochemistry (IHC) to monitor changes in Her2, Akt and Hsp70 protein levels. To monitor changes in Hsp70 in cancer patients treated with MPC-3100, PBMCs were collected prior to drug administration, 8 and 24 hours post-dose on Day 1 and 24 hours post-dose on Days 7 and 21 of the first treatment cycle. Hsp70 protein levels were determined by ELISA. Results: Exposure of HCT-116, NCI-N87 and DU-145 cells to MPC-3100 in vitro resulted in a time-dependent reduction in client protein levels with maximal reduction by 24 hours. The IC50 values for client protein reduction ranged from 0.1 μM to 0.5 μM, comparable to the cellular cytotoxicity values of MPC-3100 at 72 hours for the various cell lines. IHC revealed reduction in Her2 and Akt protein in N87 xenografts in mice given a single oral dose of 200 mg/kg MPC-3100 relative to tumors from animals dosed with vehicle. Healthy volunteer PBMCs exposed to 1 μM MPC-3100 for 24 hours ex vivo revealed a reduction in Akt, c-Raf and Cdk4 protein levels ranging from 50% to 90%. PBMCs from cancer patients receiving MPC-3100 showed an increase of 28 to 589 ng of Hsp70 protein per mg total protein over baseline by Day 8. The increase in Hsp70 expression was seen as early as 8 hours after the first dose and sustained through at least Day 22. Conclusions: The changes in client proteins and biomarkers observed in cells and tumor xenografts exposed to MPC-3100 confirm that the cellular cytotoxic activity and anti-tumor activity in xenografts are a result of Hsp90 inhibition. The consistent increase in Hsp70 expression in PBMCs from cancer patients receiving MPC-3100 indicates that Hsp90 function is inhibited in patients at doses that have been well tolerated in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2617. doi:10.1158/1538-7445.AM2011-2617
S57 Aerobic Training and Detraining in COPD and Healthy Controls
Authors: B. Popat, L. Latimer, L. Houchen-Wolloff, C. Bolton, M. Steiner
Journal: Thorax (2014)

<h3>Introduction</h3> Deconditioning is a key cause of exercise intolerance in COPD patients. Exercise training provides an effective method of improving aerobic exercise performance in this group. There is poor understanding on the trajectory of changes made in exercise performance between COPD and Healthy controls (HC), during aerobic training and more importantly limited data exists on the rates of detraining between the groups. <h3>Methods</h3> This study measures sub-maximal and maximal performance in response to an aerobic training programme and to a period of detraining. COPD and HC undertook 8 weeks of supervised cycling exercise training three times a week. There consequently followed a 4 week period of detraining, and resumption of pre cycling habitual activity (not engaging in regular exercise). A symptom limited incremental cycle (ramp protocol) and constant work rate (sub-maximal/endurance) cardiopulmonary exercise tests (CPET) were performed at baseline, after 4 and 8 weeks of training and after detraining. Cycling training intensity and CPET endurance work were equivalent to 65% of the Work (in Watts (W)) at VO2 Peak during the baseline CPET ramp test. Training intensity was re-set if there was any improvement during the 4-week CPET ramp test. <h3>Results</h3> 10 COPD patients (MRC 3, 2 males, age 74 years, FEV<sub>1</sub> 63.5% predicted) and 7 HC (MRC 1, 4 males, age 71 years, FEV<sub>1</sub> 111% predicted) completed the study. COPD group had lower starting training workloads (59.5 vs 121 Watts, p&lt;0.05) compared to HC. HC showed a significant increase in Peak VO2 uptake in the ramp but COPD patients only showed an increasing trend. There were however increases in the time achieved during sub-maximal testing in both groups during the 8 week training period. However during detraining, there was relative preservation in the HC but a significant reduction in endurance time in the COPD group. (All values median, unless stated) <h3>Conclusion/discussion</h3> Exercising training at moderate intensities showed no changes in maximal performance in COPD groups, compared to HC. However gains in sub-maximal performance were seen in both groups. Training induced gains in sub-maximal performance may be better preserved in HC during detraining, when compared to the COPD groups.
182 SEVERE ISCHEMIA–REPERFUSION INJURY DEFINED BY PEAK ALANINE AMINOTRANSFERASE IS A RISK FACTOR FOR NONANASTOMOTIC BILIARY STRICTURES AFTER ORTHOTOPIC LIVER TRANSPLANTATION WITH DONATION AFTER CARDIAC DEATH
Authors: K. Sebib Korkmaz, B.-J.F. de Rooij, M.J. Coenraad, A. Inderson, J. Dubbeld, H.W. Verspaget, B. van Hoek
Journal: Journal of Hepatology (2013)
Inhibition of Aldosterone Secretion by Amphenone in Man
Authors: Albert E. Renold, Jean Crabbé, Luis Hernando-Avendano, Don H. Nelson, Eric J. Ross, Kendall Emerson, George W. Thorn
Journal: New England Journal of Medicine (1957)

AMPHENONE was synthesized in 1950 by Allen and Corwin1 and has been shown to possess a high degree of biologic activity in animals2 3 4 and man.5 6 7 In animals the compound has been shown to affect the uterus and the thyroid and the adrenal glands. In man the studies carried out to date have been limited to its effects on the thyroid gland and on the adrenal cortex. The thyroid effects are qualitatively similar to those of thiourea and primarily result in inhibition of the organic binding of iodine.5 , 8 The adrenal effects appear at present to result from an inhibitory action of . . .
AB0651 Influence of corticosteroid therapy and vitamin D deficiency on bone mineral density in postmenopausal women with systemic lupus erythematosus
Authors: D. Marcetic, R. Stojanovic, R. Petrovic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Postmenopausal women with systemic lupus erythematosus (SLE) are in the risk of vitamin D deficiency (VDD) and osteoporosis. Extensive corticosteroid therapy is also very important factor for bone mineral loss. <h3>Objectives</h3> To determine the prevalence of osteoporosis and VDD in postmenopausal women with SLE and its relationship with corticosteroid therapy. <h3>Methods</h3> BMD on lumbar spine and/or hip (DEXA) and serum 25(OH)D in 33 postmenopausal women with SLE has been tested. Patients were consecutively visited the Institute of Rheumatology, Belgrade, during fall/winter season. Patients data (age, gender, menopausal status, disease duration, corticosteroid treatment) were collected. Examinees were not used vitamin D supplements. Statistical analysis was performed using SPSS 16.0. <h3>Results</h3> The study included 33 postmenopausal females with SLE, mean age 50.55±10.32 years, average disease duration 9.5±6.3 years. There were only 4 (12.1%) women with normal BMD, 21 (63.6%) with osteopenia and 8 (24.2%) with osteoporosis. There were no statistical differences in disease duration between these groups (p&gt;0,05, N.S.). However, estimated cumulative prednisone dose was 13.05 vs. 22.54 vs. 35.35 grams in females with normal BMD vs. osteopenia vs. osteoporosis, resulting in statistically significant diferences in corticosteroid cumulative dose between ostoporosis and osteopenia (p=0.033) and osteoporosis and normal BMD (p=0.044). Mean value of vitamin D has been 14.02ng/ml in females with normal BMD, 13.42ng/ml in females with osteopenia, and 18.59 ng/ml in women with osteoporosis (p&gt;0,05, N.S.). Prevalence of VDD was high - serious vitamin D deficiency (&lt;10 ng/ml) has been found in 12 (36.4%), vitamin D insufficiency (10-30 ng/ml) in 19 (57.6%), and normal 25(OH)D values in only 2 (6.1%) women. <h3>Conclusions</h3> Bone mineral loss and vitamin D deficiency are very common in SLE. There were no relationship of serum 25(OH)D level and disease duration with bone mineral density. However, extensive corticosteroid therapy was associated with osteoporosis. Considering high prevalence of osteoporosis and VDD in these group of patients, supplementation with vitamin D should be recommended to all postmenopausal women. <h3>Disclosure of Interest</h3> None Declared
ANATOMICAL CONSIDERATIONS FOR RENAL DENERVATION: PERI-ARTERIAL NERVE SIZE DISTRIBUTION IN HEALTHY SWINE
Authors: Kazuyuki Yahagi, Colby Ganey, Hiroyoshi Mori, Tobias Koppara, Christoph Lutter, Frank Kolodgie, Elena Ladich, Michael Joner, Renu Virmani
Journal: Journal of the American College of Cardiology (2016)
ELEVATED SERUM FIBRINOGEN LEVEL IS ASSOCIATED WITH LONG-TERM MAJOR ADVERSE CARDIAC EVENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
Authors: Felice Lin, Lawrence Ang, Samhita Palakodeti, Khushboo Kaushal, Andrew Huynh, Kelly Enright, Mattheus Ramsis, Shiqian Li, Phildrich Teh, Mitul Patel, Ryan Reeves, Ehtisham Mahmud
Journal: Journal of the American College of Cardiology (2015)
Successful management of arterial bleeding complicating endoscopic ultrasound-guided cystogastrostomy using a covered metallic stent
Authors: T. Iwashita, J. Lee, Y. Nakai, J. Samarasena, K. Chang
Journal: Endoscopy (2012)

A 56-year-old woman with a symptomatic pancreatic pseudocyst refractory to conservative treatment was referred to us for endoscopic ultrasound-guided pancreatic pseudocyst drainage (EUS-PPD). EUS showed a 12-cm cyst near the pancreatic body and tail. The cyst was punctured using a 19-gauge fine needle aspiration (FNA) needle from the stomach under EUS imaging, after careful examination of the intervening vessels with Doppler function ([Fig. 1]). A guide wire was coiled within the cyst, followed by dilation of the fistula with needle-knife cautery and a 10-mm balloon. However, on deflation of the balloon, arterial blood was seen spurting from the fistula ([Fig. 2]). The balloon was reinflated to tamponade the fistula for another 5 minutes to achieve temporary hemostasis. Deflation of the balloon again resulted in arterial bleeding. Attempts to locate the exact bleeding point failed due to the brisk bleeding as well as cystic fluid gushing from the fistula. Therefore, we placed an esophageal, fully covered self-expandable metallic stent (FCMS; 18 mm × 60 mm, Bonastent, Standard Sci-Tech, Seoul, Korea) across the cystogastrostomy to tamponade the bleeding vessel, which led to successful hemostasis ([Fig. 3] and [Fig. 4]). Inspection of the cyst cavity showed a blood clot without active bleeding ([Fig. 5]). The patient remained stable after the procedure and the stent was removed 1 month later with resolution of the pseudocyst.
Use of Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC): A Post-Hoc Analysis of the Glutox Study
Authors: Samson Benoit, Dube Pierre, Aucoin Nathalie, Wierzbicki Rafal, Maroun Jean, Letourneau Richard, Chen Eric, Charpentier Danielle, Couture Felix, Vincent Mark, Lepine Jean, Whitlock Pierre, Alloul Karine, Leblond Francois, Zhou Wei, Kavan Petr
Journal: Annals of Oncology (2014)
Stat Bite: Cancer Stage at Diagnosis for Medicare HMO and Fee-for-Service Patients
Authors: G. F. Riley
Journal: JNCI Journal of the National Cancer Institute (1994)

Stat Bite: Cancer Stage at Diagnosis for Medicare HMO and Fee-for-Service Patients Get access Gerald F. Riley Gerald F. Riley Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 24, 21 December 1994, Page 1821, https://doi.org/10.1093/jnci/86.24.1821 Published: 21 December 1994
OP0194 CD21-/LO Marginal Zone-Like B Cells in HCV-Related Mixed Cryoglobulinemia Vasculitis Highly Express FCRL5 Protein and are Specifically Killed by Anti-FCRL5 Immunotoxins
Authors: B. Terrier, S. Nagata, T. Ise, M. Rosenzwajg, D. Klatzmann, D. Saadoun, P. Cacoub
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Hepatitis C virus (HCV) is associated with B-cell lymphoproliferative disorders including mixed cryoglobulinemia (MC) and non-Hodgkin lymphoma. Fc receptor-like (FCRL) proteins comprise a newly identified family of immunoregulatory proteins with sequence similarity as Fc receptors. The transmembrane FCRL1-5 molecules are preferentially expressed on B lineage cells. <h3>Objectives</h3> To analyze the expression of FCRL1-5 proteins on B cells and test the cytotoxicity of specific immunotoxins on clonal B cells. <h3>Methods</h3> We analyzed by flow cytometry the expression of FCRL1-5 on B cells from 15 HCV-infected patients with type II MC, 20 HCV patients without MC and 20 healthy donors. <h3>Results</h3> We found a markedly increased expression of FCRL5 and decreased expression of FCRL1 on clonal CD21<sup>-/lo</sup> marginal zone-like B cells compared to other B cell subsets from the HCV patients and healthy donors. To evaluate FCRL5 as an immunotherapy target for HCV-related lymphoproliferation, we produced two anti-FCRL5 recombinant immunotoxins (F56-IT and F25-IT) based on anti-FCRL5 monoclonal antibodies and <i>Pseudomonas</i> exotoxin. The immunotoxins showed specific cytotoxicity against FCRL5-expressing clonal CD21<sup>-/lo</sup> marginal zone-like B cells isolated from HCV patients as well as FCRL5-transfected cell lines. In contrast, no cytotoxicity was observed against T cells or conventional B cells. <h3>Conclusions</h3> Taken together, our findings suggest that FCRL5-targeting therapies could be a specific treatment of HCV-related lymphoproliferation and other FCRL5-positive malignancies and/or autoimmune B-cell disorders. <h3>Disclosure of Interest</h3> None Declared